{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T00:21:43Z","timestamp":1760833303605,"version":"build-2065373602"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2007,12,1]],"date-time":"2007-12-01T00:00:00Z","timestamp":1196467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,12,1]],"date-time":"2007-12-01T00:00:00Z","timestamp":1196467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,10,10]],"date-time":"2019-10-10T00:00:00Z","timestamp":1570665600000},"content-version":"vor","delay-in-days":4331,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2007,12]]},"DOI":"10.1016\/j.breast.2007.10.004","type":"journal-article","created":{"date-parts":[[2007,12,1]],"date-time":"2007-12-01T03:25:17Z","timestamp":1196479517000},"page":"10-15","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"S3","title":["Reducing the risk of bone loss associated with breast cancer treatment"],"prefix":"10.1016","volume":"16","author":[{"given":"P.","family":"Hadji","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.breast.2007.10.004_bib1","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1001\/jama.285.6.785","article-title":"Osteoporosis prevention, diagnosis, and therapy","volume":"285","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.breast.2007.10.004_bib2","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(02)08761-5","article-title":"Diagnosis of osteoporosis and assessment of fracture risk","volume":"359","author":"Kanis","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.breast.2007.10.004_bib3","unstructured":"World Health Organization. WHO technical report series 921: prevention and management of osteoporosis, World Health Organization, Geneva, Switzerland, 2003."},{"key":"10.1016\/j.breast.2007.10.004_bib4","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1359\/JBMR.050609","article-title":"Identification of osteopenic women at high risk of fracture: the OFELY study","volume":"20","author":"Sornay-Rendu","year":"2005","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.breast.2007.10.004_bib5","doi-asserted-by":"crossref","unstructured":"Who are candidates for prevention and treatment for osteoporosis? Osteoporosis Int 1997;7:1\u20136.","DOI":"10.1007\/BF01623453"},{"key":"10.1016\/j.breast.2007.10.004_bib6","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1056\/NEJM199809103391104","article-title":"Endogenous hormones and the risk of hip and vertebral fractures among older women","volume":"339","author":"Cummings","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2007.10.004_bib7","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S8756-3282(02)00919-5","article-title":"Independent predictors of all osteoporosis-related fractures in healthy postmenopausal women: the OFELY study","volume":"32","author":"Albrand","year":"2003","journal-title":"Bone"},{"key":"10.1016\/j.breast.2007.10.004_bib8","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1056\/NEJM199503233321202","article-title":"Risk factors for hip fracture in white women","volume":"332","author":"Cummings","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2007.10.004_bib9","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1001\/archinte.165.5.552","article-title":"Fracture risk among breast cancer survivors. Results from the Women's Health Initiative Observational Study","volume":"165","author":"Chen","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.breast.2007.10.004_bib10","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/sj.bjc.6690188","article-title":"A high incidence of vertebral fracture in women with breast cancer","volume":"79","author":"Kanis","year":"1999","journal-title":"Br J Cancer"},{"key":"10.1016\/j.breast.2007.10.004_bib11","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1200\/JCO.2001.19.14.3306","article-title":"Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer","volume":"19","author":"Shapiro","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2007.10.004_bib12","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S0002-9343(03)00127-X","article-title":"The effects of adjuvant chemotherapy on bone density in postmenopausal women with early breast cancer","volume":"114","author":"Greep","year":"2003","journal-title":"Am J Med"},{"key":"10.1016\/j.breast.2007.10.004_bib13","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1359\/jbmr.060508","article-title":"Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230)","volume":"21","author":"Eastell","year":"2006","journal-title":"J Bone Miner Res"},{"issue":"Suppl.","key":"10.1016\/j.breast.2007.10.004_bib14","first-page":"5s","article-title":"Effect of anastrozole on bone mineral density: 5-year results from the \u2018Arimidex\u2019, Tamoxifen, Alone or in Combination (ATAC) trial","volume":"24","author":"Coleman","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2007.10.004_bib15","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0140-6736(04)17666-6","article-title":"Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years\u2019 adjuvant treatment for breast cancer","volume":"365","author":"Howell","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.breast.2007.10.004_bib16","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1470-2045(07)70003-7","article-title":"Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study","volume":"8","author":"Coleman","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2007.10.004_bib17","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1056\/NEJMoa052258","article-title":"A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer","volume":"353","author":"Thurlimann","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2007.10.004_bib18","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1093\/jnci\/dji250","article-title":"Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17","volume":"97","author":"Goss","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.breast.2007.10.004_bib19","first-page":"35","article-title":"Aromatase inhibitor-associated bone loss in breast cancer","volume":"1","author":"Hadji","year":"2007","journal-title":"Eur Oncol Dis"},{"key":"10.1016\/j.breast.2007.10.004_bib20","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1200\/JCO.2006.08.8617","article-title":"Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98","volume":"25","author":"Coates","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2007.10.004_bib21","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1200\/JCO.2003.08.017","article-title":"American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer","volume":"21","author":"Hillner","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2007.10.004_bib22","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1001\/archinte.164.10.1108","article-title":"Bone mineral density thresholds for pharmacological intervention to prevent fractures","volume":"164","author":"Siris","year":"2004","journal-title":"Arch Intern Med"},{"issue":"Suppl. 1","key":"10.1016\/j.breast.2007.10.004_bib23","first-page":"S112","article-title":"Incidence of osteoporosis in breast cancer patients\u2014baseline data from the LIBERATE trial","volume":"100","author":"Bundred","year":"2006","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2007.10.004_bib24","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1200\/JCO.2005.02.7102","article-title":"Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group","volume":"25","author":"Gnant","year":"2007","journal-title":"J Clin Oncol"},{"issue":"Suppl. 1","key":"10.1016\/j.breast.2007.10.004_bib25","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/j.breast.2006.01.005","article-title":"Improving bone health in patients with early breast cancer by adding bisphosphonates to letrozole: the Z-ZO-E-ZO-FAST program","volume":"15","author":"Aapro","year":"2006","journal-title":"Breast"},{"key":"10.1016\/j.breast.2007.10.004_bib26","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1200\/JCO.2005.05.3744","article-title":"Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer","volume":"25","author":"Brufsky","year":"2007","journal-title":"J Clin Oncol"},{"issue":"Suppl. 1","key":"10.1016\/j.breast.2007.10.004_bib27","first-page":"S25","article-title":"An integrated analysis of zoledronic acid (ZA) for prevention of aromatase inhibitor associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant letrozole (LET)","volume":"100","author":"Brufsky","year":"2006","journal-title":"Breast Cancer Res Treat"},{"issue":"Suppl. 1","key":"10.1016\/j.breast.2007.10.004_bib28","first-page":"S233","article-title":"Twenty-four month follow-up of the effect of zoledronic acid (ZA) on aromatase inhibitor-associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant letrozole (LET)","volume":"100","author":"Brufsky","year":"2006","journal-title":"Breast Cancer Res Treat"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977607002196?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977607002196?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:24:08Z","timestamp":1760775848000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977607002196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12]]},"references-count":28,"alternative-id":["S0960977607002196"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2007.10.004","relation":{},"ISSN":["0960-9776"],"issn-type":[{"type":"print","value":"0960-9776"}],"subject":[],"published":{"date-parts":[[2007,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reducing the risk of bone loss associated with breast cancer treatment","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2007.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}